Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection.
The pathogenesis of atherosclerosis in human immunodeficiency virus (HIV)-infected individuals is incompletely understood and appears to be multifactorial. Proatherogenic changes in blood and tissue lipids are associated with an increased risk of cardiovascular disease among HIV-infected subjects, and these changes may be both quantitative (dyslipidemia) and qualitative. In view of the pivotal role of dyslipidemia in the process of atherosclerosis, the increased incidence of dyslipidemia in HIV-infected individuals, and the emerging role of lipid abnormalities in systemic pathophysiologic processes such as immune activation, we review the contributions of dyslipidemia to cardiovascular risk in HIV infection.
['Kelesidis|Theodoros|T|', 'Currier|Judith S|JS|']
D002318:Cardiovascular Diseases D050171:Dyslipidemias D015658:HIV Infections D015497:HIV-1 D054884:Host-Pathogen Interactions D006801:Humans D050356:Lipid Metabolism D012307:Risk Factors
Dyslipidemia Cardiovascular risk Human immunodeficiency virus Antiretroviral therapy